Guilford Gliadel NDA to be filed in February for brain tumors for first- and second-line use.
GUILFORD LIKELY TO FILE GLIADEL NDA FOR TREATMENT OF GLIOMA IN FEBRUARY, VP-Business Development Nicholas Landekic stated at Hambrecht & Quist's annual health care conference Jan. 9 in San Francisco. "We originally planned to submit the NDA in December but decided to delay the submission briefly in order to broaden our proposed indication for the inclusion of the European clinical trial data, which would allow us to apply for an indication for all patients undergoing surgery for malignant gliomas," he said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth